RxDoctor Payments Data

Robert Palandjian, DO

Family Medicine · Wilmington, DENPI 1164420360

Payments from drug & device makers

$2,133in general payments, 2019–2025

Across 122 payments — averaging $17.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$637
  • Astellas Pharma US Inc$310
  • AstraZeneca$288
  • AbbVie$200
  • Merck$107
  • Boehringer Ingelheim$95
  • plus $497 from 15 others

What the payments were for

  • Food & beverage$2,05896%
  • Education$754%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,133 in reported general payments places this provider in the 75th percentile of 352 family medicine providers in Delaware.

See all family medicine providers in Delaware

Medicare billing

Part B allowed, 2024
$250,953
Medicare patients
512
Services billed
3,509

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin40$48,827
MounjaroTirzepatide31$38,265
OzempicSemaglutide30$32,792
EliquisApixaban30$31,777
SynjardyEmpagliflozin/Metformin Hcl32$30,668
JanuviaSitagliptin Phosphate25$24,408
LinzessLinaclotide15$15,532
MyrbetriqMirabegron24$15,172
Trelegy ElliptaFluticasone/Umeclidin/Vilanter11$10,856
Rosuvastatin Calcium544$10,287
Ezetimibe286$9,559
LivaloPitavastatin Calcium17$7,942
SymbicortBudesonide/Formoterol Fumarate35$7,640
Atorvastatin Calcium673$6,303
Pitavastatin Calcium13$4,867

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Synjardy$95$79,49572 claims
Lilly USA, LLCMounjaro, Olanzapine$42$40,48844 claims
Novo NordiskOzempic$13$32,79230 claims
PfizerEliquis$35$31,77730 claims
MerckJanuvia$107$24,40825 claims
AbbVieLinzess$200$15,53215 claims
Astellas Pharma US IncMyrbetriq$310$15,17224 claims
GSKTrelegy Ellipta$37$10,85611 claims
Kowa Pharmaceuticals America, Inc.Livalo$12$7,94217 claims
AstraZenecaSymbicort$288$7,64035 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 352 family medicine providers in Delaware.

Other family medicine in Wilmington

See the full list for Delaware

Where these figures come from

Is this you, or does something look wrong? →